發(fā)布時間：2019-02-14 17:57

【摘要】：本文對神經(jīng)激肽-1受體拮抗劑藥動學、藥效學、臨床研究、安全性等方面的研究進展進行綜述。歸納和整理近幾年有關神經(jīng)激肽-1受體拮抗劑的文獻報道和臨床研究數(shù)據(jù)。神經(jīng)激肽-1受體拮抗劑通過與神經(jīng)激肽-1受體高選擇性、強親和力的結合,拮抗P物質(zhì)的致吐作用,有效降低化療相關惡心嘔吐的發(fā)生,與5-羥色胺3受體拮抗劑和地塞米松聯(lián)用相比于后兩者聯(lián)用可有效提高化療患者的完全緩解率(P0.05),尤其在延遲期療效顯著(P0.05),且具有很好的安全性以及成本-效果優(yōu)勢。除此之外,對術后相關的惡心嘔吐、瘙癢、腫瘤等的治療也具有很好的療效。神經(jīng)激肽-1受體拮抗劑是防治化療相關惡心嘔吐的新突破,前景廣闊,但臨床還應對該類藥物進行更深入的研究。
[Abstract]:This article reviews the pharmacokinetics, pharmacodynamics, clinical research and safety of neurokinin-1 receptor antagonists. The literature and clinical data of neurokinin-1 receptor antagonists were summarized and summarized in recent years. Neurokinin-1 receptor antagonist can effectively reduce the occurrence of chemotherapy-associated nausea and vomiting by combining with neurokinin-1 receptor with high selectivity and strong affinity. In combination with serotonin 3 receptor antagonist and dexamethasone, the complete remission rate of chemotherapy patients was significantly increased (P0.05), especially in the delayed period (P0.05). And has the very good security and the cost-effect superiority. In addition, the treatment of postoperative nausea and vomiting, itching, tumor and so on also has the very good curative effect. Neurokinin-1 receptor antagonist is a new breakthrough in the prevention and treatment of chemotherapy-related nausea and vomiting.
【作者單位】： 北京大學醫(yī)學部藥學院藥事管理與臨床藥學系;北京醫(yī)院藥學部;
【分類號】：R979.1

【共引文獻】

相關期刊論文 前10條

1 方振威;翟所迪;;阿瑞吡坦防治化療致惡心嘔吐的Meta分析[J];北京大學學報(醫(yī)學版);2010年06期

2 周鵬飛;徐�；�;周晉華;;足三里穴位注射防治化療嘔吐的研究進展[J];中醫(yī)藥臨床雜志;2013年10期

3 屈淑賢;鄭振東;劉兆U，

本文編號：2422454